about
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells.Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cellsRole of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyBase excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDXAcross the universe of K-RAS mutations in non-small-cell-lung cancer.Genetic markers for prediction of treatment outcomes in ovarian cancer.Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo.∆Np73beta induces caveolin-1 in human non-small cell lung cancer cell line H1299.The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugsDNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer.Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approachExploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialMetformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC
P50
Q34104005-CCCDDE7C-6D2B-4535-BA0C-389051A46763Q34202863-D6B78EF5-42A1-4C85-B521-085F5902C3B8Q36287562-A8673916-3D34-47F8-8D64-FE3D384D1648Q36545375-E6B8A665-7CCA-48ED-B0C9-99BCA60FE2B6Q36557507-67D2CFF4-4A63-45D5-8322-CA7FF2029369Q37346174-E40CC852-A87B-461C-BA9A-72542B3A4EB5Q38153826-B79F35DB-97FA-4DD2-BF75-CAA2B6776FE2Q38227080-BA234B5D-2AE7-409F-9D12-224EB6728BFEQ38762944-06025BD5-FCDA-4FF4-8952-4A762376587FQ38838216-BB5EC294-A7BB-4DF7-B726-489B7BA81663Q39102558-2F4062CB-2444-4EB6-8729-89E7EC130822Q40659578-F3E06242-6E8D-42B3-BE62-7940D3DF43C6Q40810940-C187F6DE-6F82-4105-A570-6B8A9F7C4DD8Q41949668-E0A289EE-B35A-4E38-8E95-723F324A99C5Q42330188-47A58BFE-C7CA-4075-8075-475CC4FDD6BAQ44386340-91976779-2AB6-44E7-8695-2F10FE76A223Q48223594-A2FC47C1-FDEE-4798-9577-E080E94D5841Q59793918-CEC98358-E5CC-445F-B6AE-411CEE93E0A5Q90928136-436F5AEC-57B2-4F60-A366-08B6759EF12CQ91159351-E0EAE651-8FFE-41F3-A6DF-251415D7CD4E
P50
description
researcher ORCID ID = 0000-0002-9624-5533
@en
wetenschapper
@nl
name
E Caiola
@ast
E Caiola
@en
E Caiola
@es
E Caiola
@nl
type
label
E Caiola
@ast
E Caiola
@en
E Caiola
@es
E Caiola
@nl
prefLabel
E Caiola
@ast
E Caiola
@en
E Caiola
@es
E Caiola
@nl
P106
P1153
36547312500
56244222300
P31
P496
0000-0002-9624-5533